Cytoreductive Nephrectomy After Combination of Nivolumab Plus Ipilimumab for Mucinous Tubular and Spindle Cell Carcinoma of the Kidney With Bone Metastases: A Case Report

Furubayashi, Nobuki; Taguchi, Kenichi; Negishi, Takahito; Miura, Akihiro; Sato, Yoshinori; Miyoshi, Makoto; Nakamura, Motonobu

doi:10.21873/invivo.12732

Cited by 3 publications

(1 citation statement)

References 31 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are reports on the treatment of spindle cell carcinoma with ipilimumab+nivolumab; this regimen has been reported to be effective against renal mucinous tubular and spindle cell carcinoma. 4 In this case, PD‐L1 expression was negative, and excluding first‐line treatment with a single ICI. Notably, no reports exist on using the use the ipilimumab+nivolumab regimen for lung spindle cell carcinoma.…”

Section: Discussionmentioning

confidence: 80%

Effective management of lung spindle cell carcinoma with ipilimumab, nivolumab, carboplatin, and paclitaxel, demonstrating efficacy in brain metastases treatment

Noguchi,

Okamoto,

Nohara

et al. 2024

Respirology Case Reports

View full text Add to dashboard Cite

A 76‐year‐old woman with cT1bN2M1b stage IVA spindle cell carcinoma of the right lower lobe of the lung, no driver gene mutation, and programmed death ligand 1 < 1%, was started on ipilimumab+nivolumab+carboplatin+paclitaxel. After two courses, the patient initiated maintenance therapy with ipilimumab+nivolumab. New multiple brain metastases were observed during treatment but resolved with continued treatment. We report a unique case of spindle cell carcinoma treated with ipilimumab+nivolumab+carboplatin+paclitaxel that resulted in long‐term response and resolution of new brain metastasis.

show abstract

Section: Discussionmentioning

confidence: 80%

Effective management of lung spindle cell carcinoma with ipilimumab, nivolumab, carboplatin, and paclitaxel, demonstrating efficacy in brain metastases treatment

Noguchi,

Okamoto,

Nohara

et al. 2024

Respirology Case Reports

View full text Add to dashboard Cite

show abstract

Nivolumab

2022

Reactions Weekly

View full text Add to dashboard Cite

Activity of Immunotherapy Regimens on Primary Renal Tumours: A Systematic Review

Jones

Ince

Welsh

et al. 2022

KCA

View full text Add to dashboard Cite

BACKGROUND: Immune checkpoint inhibitors (ICPIs) are widely used in treating metastatic renal cell carcinoma (RCC). Cytoreductive nephrectomy (CN) forms part of multimodality treatment in advanced disease, however there is no prospective evidence for its use in the ICPI era. Trials of neoadjuvant ICPIs in RCC are underway; understanding the anticipated effect of ICPIs on the primary tumour may help clinical decision making in both localised and advanced settings. METHODS: A systematic search (PubMed, Web of Science, clinicaltrials.gov) of English literature from 2012 to 2022 was performed according to PRISMA guidelines. 2,398 records were identified, 54 were included in the analysis. RESULTS: In the metastatic setting, response in the primary tumour (≥30% reduction in size) is seen in 33–56% of patients treated with dual ICPI or ICPI + VEGFR-TKI. Pathological complete response rates were 14% for patients undergoing CN after a period of ICPI therapy. In the neoadjuvant setting there is a single published trial of VEGFR-TKI + ICPI, 30% of patients had a≥30% reduction in size of the primary. This appears superior to single agent ICPI. Grade 3 adverse event rates are comparable to the metastatic setting. CONCLUSIONS: A period of ICPI combination therapy followed by nephrectomy may be considered for selected patients as a strategy to manage metastatic disease. In the neoadjuvant setting, it is not clear whether ICPI + VEGFR-TKI is superior to VEGFR-TKI alone. There is minimal data on whether either CN after ICPI in metastatic patients, or neoadjuvant ICPI therapy for localised disease, improves long term survival.

show abstract

Cytoreductive Nephrectomy After Combination of Nivolumab Plus Ipilimumab for Mucinous Tubular and Spindle Cell Carcinoma of the Kidney With Bone Metastases: A Case Report

Cited by 3 publications

References 31 publications

Effective management of lung spindle cell carcinoma with ipilimumab, nivolumab, carboplatin, and paclitaxel, demonstrating efficacy in brain metastases treatment

Effective management of lung spindle cell carcinoma with ipilimumab, nivolumab, carboplatin, and paclitaxel, demonstrating efficacy in brain metastases treatment

Nivolumab

Activity of Immunotherapy Regimens on Primary Renal Tumours: A Systematic Review

Contact Info

Product

Resources

About